Clinical Section / Viewpoint

Gerontology
DOI: 10.1159/000442746

Living Long and Well: Prospects for a Personalized Approach to the Medicine of Ageing

Georg Fuellen a, Paul Schofield l, m, Thomas Flatt k, Ralf-Joachim Schulze e, Fritz Boege g, Karin Kraft b, Gerald Rimbach h, Saleh Ibrahim i, Alexander Tietz f, Christian Schmidt c, Rüdiger Köhling d, Andreas Simm j

a Institute for Biostatistics and Informatics in Medicine und Ageing Research (IBIMA), b Chair of Complementary Medicine, c Office of the Medical Director, and d Oscar Langendorff Institute of Physiology, Rostock University Medical Center, Rostock, e Department of Geriatric Medicine, St. Marien-Hospital, and f Gesellschaft für Gesundes Altern und Prävention, Cologne, g Institute of Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, Heinrich Heine University, Düsseldorf, h Institute of Human Nutrition and Food Science, University of Kiel, Kiel, i Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, and j Clinic for Cardiothoracic Surgery, University Hospital Halle, Halle (Saale), Germany; k Department for Ecology and Evolution, University of Lausanne, Lausanne, Switzerland; l Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK; m The Jackson Laboratory, Bar Harbor, Maine, USA

Key Words
Health span · Healthy ageing · Cohort study · Model organism · Bioinformatics

Abstract
Research into ageing and its underlying molecular basis enables us to develop and implement targeted interventions to ameliorate or cure its consequences. However, the efficacy of interventions often differs widely between individuals, suggesting that populations should be stratified or even individualized. Large-scale cohort studies in humans, similar systematic studies in model organisms as well as detailed investigations into the biology of ageing can provide individual validated biomarkers and mechanisms, leading to recommendations for targeted interventions. Human cohort studies are already ongoing, and they can be supplemented by in silico simulations. Systematic studies in animal models are made possible by the use of inbred strains or genetic reference populations of mice. Combining the two, a comprehensive picture of the various determinants of ageing and ‘health span’ can be studied in detail, and an appreciation of the relevance of results from model organisms to humans is emerging. The interactions between genotype and environment, particularly the psychosocial environment, are poorly studied in both humans and model organisms, presenting serious challenges to any approach to a personalized medicine of ageing. To increase the success of preventive interventions, we argue that there is a pressing need for an individualized evaluation of interventions such as physical exercise.

This paper is derived from a discussion at the ‘Hauptstadtkongress 2014’ (http://www.hauptstadtkongress.de/index.php?id=76&id_programm=103) on ‘Regeneration and slowing down ageing in the world of tomorrow’.

KARGER © 2015 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/ger

© 2015 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/ger

Georg Fuellen
Institute for Biostatistics and Informatics in Medicine and Ageing Research (IBIMA)
Rostock University Medical Center, Ernst-Heydemann-Strasse 8
DE–18057 Rostock (Germany)
E-Mail fuellen@alum.mit.edu
cise, nutrition, nutraceuticals and calorie restriction mimetics as well as psychosocial and environmental factors, separately and in combination. The expected extension of the health span enables us to refocus health care spending on individual prevention, starting in late adulthood, and on the brief period of morbidity at very old age.

Introduction

The need for ageing research is growing rapidly. Trends predicted from the EUROPOP survey suggest that the proportion of the population aged 65 years and over will rise from 17% in 2010 to 30% in 2060, with those aged over 80 years increasing from 5 to 12% over the same period (http://futurage.group.shef.ac.uk/roadmap.html). The economic and social consequences of the fact that the population is ageing therefore cannot be overestimated. Slowing down the deleterious processes of ageing itself would allow significant benefits beyond those of eradicating specific diseases – which, e.g. in the case of cancer and stroke, amount to life span extensions of just a few years [1]. Diseases of age, whether cardiovascular, neoplastic, pulmonary or cognitive, are increasing in frequency and will be the top 4 causes of death worldwide by 2020; 75% of all deaths from these diseases occur in people aged 60 years and over, and their incidence rises with age. In other words, for a host of non-communicable diseases, there is a clear link between the underlying processes of ageing and the age-dependent accumulation of risk, so that the eradication of one disease merely makes way for the occurrence of another disease slightly later [2–4]. Slowing down ageing itself, and addressing its root mechanisms, is expected to increase 'health spans' and to compress the period of age-related morbidity, thus tackling goals considered much more worthwhile than simply extending the chronological life span [3, 4]. Moreover, for any interventions, the effects of genotype and environment (biological and psychosocial) and the interaction between the underlying mechanisms are most important, and their combinatorial application should be considered (fig. 1).

Therefore, based on the recent convergence of personalized medicine and ageing research in human and model organisms, we suggest in this viewpoint paper that a successful research agenda for the next decade should be based on three pillars (fig. 2): (1) extending,
complementing and integrating the knowledge base assembled in existing human cohort studies; (2) running closely similar studies in animal models, and (3) understanding the biology of ageing through the detailed investigation of findings in humans and animals to gain a mechanistic understanding of biomarkers and interventions.

Our agenda rests on the biomarker concept. Baker and Sprott [5] defined a biomarker of ageing as ‘a biological parameter of an organism that either alone or in some multivariate composite will, in the absence of disease, better predict functional capability at some late age, than will chronological age’; the American Federation for Aging Research has proposed more detailed criteria for biomarkers of ageing aimed at estimating biological, not chronological age [6]; essentially adding their close relation to processes that underlie ageing, not disease, their ease of measurement and their cross-species relevance. However, while many biomarkers of ageing were described in animal or cross-sectional human studies, most of them failed in the few long-term human studies available [7]. One problem lies in technical limitations: human marker measurements are rarely comparable across decades. Also, by selecting blood as the most easily assayable biological fluid, other organs affected by age are ignored. Moreover, there are major variations during the day or the year, as e.g. the amount of daylight will have an impact on many markers. Also, some markers such as a low body mass index or blood pressure may indicate a lower biological age for younger people and the opposite for the very old [8, 9]. Finally, while biomarkers should describe biological age, there is no true ‘gold standard’ – which would need to be based on a comprehensive longitudinal study in humans running for almost a century. Studies of populations at an advanced age, such as the Leiden or Newcastle 85+ studies [10, 11], necessarily focus on old-age multimorbidity rather than on the full spectrum of ageing processes over a human life course. Nevertheless, listings of biomarkers validated for humans in longitudinal studies were compiled; they include interleukin 6 (IL-6) and some hormones [7, 12], as well as, more recently, galactosylated N-glycans [13], plasma N-terminal pro-B-type natriuretic peptide [14] and epigenetic markers [15, 16].

‘Personalized’ approaches to medicine are gaining ground in mainstream medical research. The most well-known of these involve cancer therapeutic agents with a companion diagnostic gene test, such as Herceptin™ and Gleevec™ [17]. More comprehensive, ‘omics’-based attempts at personalizing diagnostics and therapy are being tested [18]. Moreover, molecular markers and interventions have to be integrated with biographical ones [19]. Assembling sufficiently large human data sets in order to allow a differentiation and classification of patients within cohorts is the key to personalized medicine. Longitudinal cohort studies, such as the Framingham Heart Study [20] and the Study of Health in Pomerania (SHIP) [21] or the upcoming German National Cohort [22], therefore attempt to identify disease mechanisms, risk factors, prevention strategies and early markers in the general population; systematic integration of such data is also being attempted (http://www.chancesfp7.eu/).

While the mechanisms of ageing are complex [4, 23, 24], evidence is accumulating that ageing is a potentially modifiable risk factor [25] for morbidities associated with it. Moreover, longitudinal cohort studies in humans (see above) and primates [26, 27], human genome-wide association studies [28] as well as longitudinal studies, genetic manipulation and intervention testing programs for rodents [29–31] have yielded many insights in recent years. Some of them converge on exercise and diet and their associated pathways. In particular, one of the recurring themes is that of pathways related to energy and nutrient sensing and production [32], and dietary restriction has emerged as the most robust means of extending life spans and health spans alike [26]. Dietary restriction may be the best path towards this goal, even though its long-term effects on humans are ultimately unknown. Pragmatically speaking, its downside is that it requires behavioral modifications and great willpower, triggering the search for calorie-restriction mimetics, i.e. small molecules that produce comparable effects, with some of them promising early results [33]. Importantly, the effects of dietary restriction are not uniform; in the case of mice and primates, the results of dietary restriction vary by genotype (or strain or subspecies), diet and/or environment, and dietary restriction was sometimes found to be detrimental [34], just as the effects of its mimetics vary [35]. The effects of dietary components vary as well; for instance, whole-grain bread tends to have positive effects mostly in Northern European populations and less in Mediterranean people [36]. Similarly, the effects of fish oil in mice and humans depend on the APOE genotype [37]. Thus, we may expect to find a high degree of heterogeneity in the informativity of biomarkers, or the efficacy of interventions, for humans and outbred animals alike. Moreover, studies of the underlying molecular mechanisms in terms of pathways may also wish to take into account individual variability.
Personalized Medicine and Ageing Research Are Now Starting to Come Together, Aided by the Explorative and Confirmatory Power of High-Throughput Data Sets

The most visible sign of the convergence of personalized medicine and ageing research is the recent start-up of Human Longevity Inc. (http://www.humanlongevity.com/) by Craig Venter, aiming at finding genomic, metabolomic, microbiomic and other determinants of health in hundreds of thousands of volunteers. Along similar lines, the Institute for Systems Biology in Seattle is now pursuing the 100K Wellness Project (http://research.systemsbiology.net/100k/). As time goes by, longitudinal cohort studies will by necessity be developing into studies of ageing, and a few are explicitly gathering data with the aim of fostering a better understanding of ageing processes [38, 39]. Longitudinal studies in model organisms permit a systematic dissection of the molecular architecture of ageing. For example, around 30 strains of mice have recently been studied at the Nathan Shock Center of the Jackson Laboratory [29], and phenotypic and/or genetic data are now being analyzed together with life span data [9, 40, 41]. Efforts such as the Collaborative Cross [42] allow genome-wide association study-like trials in mice as well as the subsequent detailed study of mechanistic insights and, more generally, the modeling of approaches to personalized medicine in animals. Here, we can investigate in great detail the individual differences in the biology of ageing on the cell, tissue and organ level. On each of these levels, the speed of ageing can vary substantially, and this may, for instance, be reflected epigenetically [15, 16]. More generally, as described in the Introduction, biomarkers of ageing are usually found while investigating subpopulations (such as people aged 85 years and older), and these biomarkers also allow the stratification of large populations according to the biology of ageing.

Whilst association studies may provide information on personal risks for specific morbidities as well as on their severity and timing, many of these risks are turning out to be modified by subjects’ psychosocial environment and individual history, which in themselves need to be included not only as part of the risk analysis but also as a guide to potential therapies [43]. Many associations with ageing and age-related diseases such as Alzheimer’s are complex, often with low effect sizes of individual variants, and it is highly likely that at least some of the missing heritability is due to environmental interactions [44]. For example, in a mouse model, the disease risk in predisposed strains was shown to be attenuated by environmen-
processes are subtler, triggering weaker patterns and signals in terms of phenotype and molecular mechanisms, and on a longer timescale. Therefore, the sound integration of data using the techniques of data semantics and ontologies is important in ageing research [53–56] to maximize our chances of detecting meaningful patterns and signals.

The Implementation of Any Recommendations for Health Span Extension Must Be Easy and Safe

Many people show close adherence to moderate modifications of exercise and dietary patterns, motivated by their personal instinct or subjective feelings of benefit. The correct use of and long-term adherence to changes in dietary composition, nutraceuticals and food supplements is more difficult, though. Healthy and health-conscious individuals consuming high amounts of fruit and vegetables (>400 g/day) display a more robust organismal antioxidant defense system [57] and a better cognitive performance [58], independent of their age and gender, compared to subjects consuming <100 g/day, although a good plasma micronutrient status can be achieved through targeted counseling [59]. However, as the correct use of nutraceuticals and food supplements is complicated [60], most of the supplementation trials with single compounds and/or single lifestyle preventive strategies against age-related diseases have largely been unsuccessful so far [61]. Furthermore, an immediate subjective feeling of benefit with nutraceuticals is not usually attained, while their possible physiological impact may be significant (on the positive as well as on the negative side). This also applies to long-term small-molecule interventions such as calorie-restriction mimetics. Additionally, the quality and safety of nutraceuticals and food supplements are not controlled as strictly as drugs. Here, subjective feelings have to be supplemented with or substituted by sound scientific evidence regarding benefits, subject to a personalized approach. The polypill concept [62] is often criticized exactly because it does not consider the specifics of the individual. It consists of intensively tested drugs at low dosage, the benefits of which have been shown in large-scale studies. Specifically, it aims to reduce the risk of heart attacks and strokes, employing one statin and three blood pressure-reducing agents at around half the standard dose; in a personalized instantiation, it can be considered a model for active interventions to stay healthy for longer periods of time.

Sound Scientific Evidence for Health Span Effects of Interventions in Humans Is Becoming Available

Conclusive evidence for therapeutic or prophylactic effects of interventions on the human health span is going to be difficult to establish, since longitudinal intervention studies (starting in midlife) would take around half a century to complete. Moreover, interventions designed for presumably healthy people need specific justification and should have no discernible negative side effects. However, a significant postponement of ageing-associated disease and morbidity is a distinctly positive aim that should not be abandoned without due consideration. Fortunately, there are a couple of convincing arguments that indicate a high likelihood of success in finding valid means for achieving health span extensions [25], with people in their late adulthood as the target group. First, very ‘mild’ forms of health span-extending interventions have already been practiced for a long time; their systematic and personalized improvement is already half the battle. Such interventions include exercise, diet and nutraceuticals, as well as indication-based interventions such as drug-based blood pressure reduction, cholesterol modulation and osteoporosis prevention. Also, for many individuals, a further significant extension of their health span can be expected from improvements in their psychosocial environment, social participation and education. While consistent good parental care in the early years is a good foundation, psychosocial lifestyle interventions can still be effective in adulthood [19]. Second, as a proof of concept, dietary restriction has already been demonstrated to extend health spans in numerous animal species including mammals – benefitting rhesus monkeys, for example (see above) – and has been shown to improve biomarkers of ageing in humans in late adulthood as well [63]. Moreover, as described above, pharmacological mimetics of dietary restriction have shown promising results, at least in mouse studies [33]. Combining interventions is important, though, since most of the supplementation trials with single compounds and/or single lifestyle preventive strategies have largely been unsuccessful so far [61]. Third, centenarians frequently feature very late onsets of age-related diseases and disabilities [64], demonstrating that the goal of health span extension can indeed be accomplished at a very old age.

1 For example, a 6-year study on the prevention of dementia failed to show positive effects, possibly due to increasing nonadherence [68] (fig. 2 therein).
Conclusions and Prospects

We propose a realistic research agenda with distinctive positive advances within one decade:

- We need to augment ongoing and future clinical studies, measuring as many ageing-related parameters as possible, and to couple them with closely similar animal studies, which feature far shorter execution times and more possibilities for experimental intervention and detailed study. Here, one main aim is to discover and validate new markers of ageing which may assist in the stratification of populations with regard to the efficacy of therapeutic and prophylactic interventions. It is critical to record environmental parameters as well as the characteristics of stress, activity and personal history for human studies and to conduct detailed analyses of the effects of the environment for model organism studies.

- We need to systematically validate the evidence gained from model animal studies in humans and vice versa. Here, we need an in-depth understanding of the molecular processes that are supposed to be the targets of an intervention. Mechanistic studies in mice are essential, and studies in humanized mice, (human) cell lines and other model organisms should be undertaken as well, always selecting the most informative approach.

- Finally, given the range of interventions likely to become validated and available, we should aim for a combinatorial approach through the establishment of a modular system, from which the most appropriate combination of interventions (fig. 1) can be selected by any individual.

Such an agenda can be expected to yield validated personalized prescriptions for many people within a decade, enabling them to extend their health span and to shorten the period of their life that is spent in ill health.

Economic Implications

Slowing ageing and extending health spans has profound economic implications. Importantly, maintaining health and fitness for a longer time period allows later retirement and more senior-level contributions to society (http://www.healthyageing.eu/). Furthermore, with the growing shortage of young employees there is a great need for people working until the age of 70 years or more, especially in service industries such as medicine. Most importantly, however, increases in health span are among the few contributors to lowering health care costs in a predictable way by postponing most of the demand until very old age [65]. The current repair-oriented approaches adopted in cancer, cardiovascular diseases, neurodegeneration and other areas may then slowly but steadily be refocused on serving populations at an increasingly advanced age who stay healthy well beyond their 90s. In summary, the social, economic and health-related benefits resulting from prolonging health spans are ‘longevity dividends’ [66].

Acknowledgements

G.F. was supported in part by the BMBF Verbundprojekt ROSAge, FKZ 0315892A and the EU Horizon 2020 research and innovation program under grant agreement No. 633589; A.S. was supported in part by the state of Saxony-Anhalt.

Disclosure Statement

The authors declare that they have no conflicts of interest.

References

A Personalized Approach to the Medicine of Ageing

Gerontology
DOI: 10.1159/000442746